Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 10 therapeutic classes by estimated global pharmaceutical sales in 2017 (in billion U.S. dollars)

Exclusive Premium Statistic

Top therapeutic classes by global pharmaceutical sales 2017 estimates This statistic depicts the top 10 therapeutic classes by global pharmaceutical sales in 2017. In that year, the global pharmaceutical industry is estimated to generate a total revenue of some 36 billion U.S. dollars through mental health drug spending.
Top therapeutic classes and drugs

Oncologics, pain therapy, and anti-diabetics are among the top global pharmaceuticals based on revenues, generating 81 billion U.S. dollars, 76 billion U.S. dollars, and 72 billion U.S. dollars, respectively, in 2017. In oncologic developments, drugs for non-small cell lung cancer and breast cancer were among the leading diseases in therapeutic drug development. On the other hand, mental health drugs like Cymbalta generated over 36 billion dollars of revenue worldwide. Cymbalta is manufactured by Eli Lilly and used to treat major depressive disorder and generalized anxiety disorder.

One of Bristol-Myers Squibb’s most profitable medications was Abilify, a neurology product that generated revenue of 5.8 billion U.S. dollars in the United States in 2015. Aripiprazole, marketed as Abilify, is used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, among other disorders. Bristol-Myers Squibb’s neuroscience program focuses on the development of therapeutic regimens for disorders that impact the brain and nervous systems. Some of the company’s other therapeutic areas of focus include cardiovascular, immunoscience, and virology.
Show more
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Sales in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--
Sales in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

© Statista 2018

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic depicts the top 10 therapeutic classes by global pharmaceutical sales in 2017. In that year, the global pharmaceutical industry is estimated to generate a total revenue of some 36 billion U.S. dollars through mental health drug spending.
Top therapeutic classes and drugs

Oncologics, pain therapy, and anti-diabetics are among the top global pharmaceuticals based on revenues, generating 81 billion U.S. dollars, 76 billion U.S. dollars, and 72 billion U.S. dollars, respectively, in 2017. In oncologic developments, drugs for non-small cell lung cancer and breast cancer were among the leading diseases in therapeutic drug development. On the other hand, mental health drugs like Cymbalta generated over 36 billion dollars of revenue worldwide. Cymbalta is manufactured by Eli Lilly and used to treat major depressive disorder and generalized anxiety disorder.

One of Bristol-Myers Squibb’s most profitable medications was Abilify, a neurology product that generated revenue of 5.8 billion U.S. dollars in the United States in 2015. Aripiprazole, marketed as Abilify, is used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, among other disorders. Bristol-Myers Squibb’s neuroscience program focuses on the development of therapeutic regimens for disorders that impact the brain and nervous systems. Some of the company’s other therapeutic areas of focus include cardiovascular, immunoscience, and virology.
Show more
Release date
March 2018
Region
Worldwide
Survey time period
as of October 2017
Supplementary notes
The statistic includes 8 developed and 6 pharmerging countries: U.S., EU5, Japan, Canada, China, Brazil Russia, India, Turkey, Mexico.

Statista Accounts: Access All Statistics. Starting from $588 / Year

Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
With Statista, you get straight to the point: analyzing data, rather than searching for it.
Dr. Antonella Mei-Pochtler

Dr. Antonella Mei-Pochtler
Senior Vice President, Boston Consulting Group

Statistics on "Global pharmaceutical industry"

  • Overview
The most important statistics
  • Companies and products
  • Top companies by revenue
  • R&D, patents, new entities
  • Outlook
The most important statistics
Statista for your company

Saves time and money: instant access to this and 1 million more statistics.
Access to dossiers, industry reports and many other studies.

Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.